147 related articles for article (PubMed ID: 31687889)
21. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans.
Shen L; Frazer-Abel A; Reynolds PR; Giclas PC; Chappell A; Pangburn MK; Younis H; Henry SP
J Pharmacol Exp Ther; 2014 Dec; 351(3):709-17. PubMed ID: 25301170
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
Burel SA; Han SR; Lee HS; Norris DA; Lee BS; Machemer T; Park SY; Zhou T; He G; Kim Y; MacLeod AR; Monia BP; Lio S; Kim TW; Henry SP
Nucleic Acid Ther; 2013 Jun; 23(3):213-27. PubMed ID: 23692080
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice.
Kim TW; Papagiannis CN; Zwick LS; Engelhardt JA; Hoffmaster CM; Post NM; Matson JE; Hsiao JA; Burel SA; Henry SP
Toxicol Pathol; 2019 Jan; 47(1):82-92. PubMed ID: 30585133
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals.
Swayze EE; Siwkowski AM; Wancewicz EV; Migawa MT; Wyrzykiewicz TK; Hung G; Monia BP; Bennett CF
Nucleic Acids Res; 2007; 35(2):687-700. PubMed ID: 17182632
[TBL] [Abstract][Full Text] [Related]
27. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
[TBL] [Abstract][Full Text] [Related]
28. Materials in Manufacturing and Packaging Systems as Sources of Elemental Impurities in Packaged Drug Products: An Updated Literature Review.
Jenke D
PDA J Pharm Sci Technol; 2020; 74(3):324-347. PubMed ID: 31843988
[TBL] [Abstract][Full Text] [Related]
29. Qualification of impurities based on metabolite data.
Weidolf L; Andersson T; Bercu JP; Brink A; Glowienke S; Harvey J; Hayes MA; Jacques P; Lu C; Manevski N; Muster W; Nudelman R; Ogilvie R; Ottosson J; Teasdale A; Trela B
Regul Toxicol Pharmacol; 2020 Feb; 110():104524. PubMed ID: 31734179
[TBL] [Abstract][Full Text] [Related]
30. Metabolism and Disposition of Volanesorsen, a 2'-
Post N; Yu R; Greenlee S; Gaus H; Hurh E; Matson J; Wang Y
Drug Metab Dispos; 2019 Oct; 47(10):1164-1173. PubMed ID: 31350288
[TBL] [Abstract][Full Text] [Related]
31. Analytical control of process impurities in Pazopanib hydrochloride by impurity fate mapping.
Li Y; Liu DQ; Yang S; Sudini R; McGuire MA; Bhanushali DS; Kord AS
J Pharm Biomed Anal; 2010 Aug; 52(4):493-507. PubMed ID: 20189340
[TBL] [Abstract][Full Text] [Related]
32. Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development.
Harvey J; Fleetwood A; Ogilvie R; Teasdale A; Wilcox P; Spanhaak S
Regul Toxicol Pharmacol; 2017 Mar; 84():116-123. PubMed ID: 28038978
[TBL] [Abstract][Full Text] [Related]
33. Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.
Crooke ST; Baker BF; Kwoh TJ; Cheng W; Schulz DJ; Xia S; Salgado N; Bui HH; Hart CE; Burel SA; Younis HS; Geary RS; Henry SP; Bhanot S
Mol Ther; 2016 Oct; 24(10):1771-1782. PubMed ID: 27357629
[TBL] [Abstract][Full Text] [Related]
34. Acute hepatotoxicity of 2' fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins.
Shen W; De Hoyos CL; Sun H; Vickers TA; Liang XH; Crooke ST
Nucleic Acids Res; 2018 Mar; 46(5):2204-2217. PubMed ID: 29390093
[TBL] [Abstract][Full Text] [Related]
35. Automated determination of early eluting oligonucleotide impurities using ion-pair reversed-phase liquid chromatography high resolution-mass spectrometry.
Roussis SG; Cedillo I; Rentel C
Anal Biochem; 2020 Apr; 595():113623. PubMed ID: 32067983
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.
Henry SP; Narayanan P; Shen L; Bhanot S; Younis HS; Burel SA
Nucleic Acid Ther; 2017 Aug; 27(4):197-208. PubMed ID: 28541820
[TBL] [Abstract][Full Text] [Related]
37. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antisense properties of 2'-O-(2S-methoxypropyl)-RNA-modified gapmer antisense oligonucleotides.
Yu J; Pandey SK; Khatri H; Prakash TP; Swayze EE; Seth PP
ChemMedChem; 2014 Sep; 9(9):2040-4. PubMed ID: 24891270
[TBL] [Abstract][Full Text] [Related]
39. An antisense oligonucleotide targeting the growth hormone receptor inhibits neovascularization in a mouse model of retinopathy.
Wilkinson-Berka JL; Lofthouse S; Jaworski K; Ninkovic S; Tachas G; Wraight CJ
Mol Vis; 2007 Aug; 13():1529-38. PubMed ID: 17893652
[TBL] [Abstract][Full Text] [Related]
40. Rapid Oligonucleotide Drug Impurity Determination by Direct Spectral Comparison of Ion Pair-Reversed Phase HPLC ESI MS Data.
Roussis SG; Koch C; Capaldi D; Rentel C
Rapid Commun Mass Spectrom; 2018 Mar; ():. PubMed ID: 29575209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
